Septerna is poised for a pivotal catalyst with upcoming Phase 1 data for SEP-631, targeting mast cell-driven diseases via ...
Ouster's robust cash reserves and DoD contract provide resilience amid industry volatility and ongoing market consolidation.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results